Go Deep
IRADIMED CORPORATION
IRADIMED CORPORATION Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 17,570 | 50.1 | 11.27 | 0.00 | 8,537.70 |
| Oct 2026 | 17,550 | 50.2 | 11.29 | 0.00 | 8,529.13 |
| Oct 2026 | 17,600 | 49.9 | 11.23 | 0.00 | 8,486.67 |
| Oct 2026 | 17,721 | 49.3 | 11.09 | 0.00 | 8,360.49 |
| Oct 2026 | 17,789 | 49.0 | 11.02 | 0.00 | 8,310.66 |
| Oct 2026 | 17,724 | 49.3 | 11.09 | 0.00 | 8,366.60 |
| Oct 2026 | 17,771 | 49.1 | 11.04 | 0.00 | 8,305.26 |
| Oct 2026 | 17,790 | 49.0 | 11.01 | 0.00 | 8,272.41 |
IRADIMED CORPORATION Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 20,466,000.0 | 21,979,000.0 | 22,691,899.0 | 21,202,064.0 |
| Net Profit | 5,218,000.0 | 5,818,000.0 | 6,441,958.0 | 5,576,652.0 |
| EPS | 0.4 | 0.5 | 0.5 | 0.4 |
IRADIMED CORPORATION Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 83,814,000.0 | 73,242,000.0 | 65,562,296.0 | 53,303,145.0 | — |
| Net Profit | 22,480,000.0 | 19,234,000.0 | 17,192,776.0 | 12,828,487.0 | — |
| EPS | 1.8 | 1.5 | 1.4 | 1.0 | — |
IRADIMED CORPORATION Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 108,776,000.0 | 98,326,000.0 | 92,156,098.0 | 85,513,747.0 | — |
| Total Liabilities | 14,158,000.0 | 11,507,000.0 | 20,735,934.0 | 11,840,760.0 | — |
| Total Equity | 94,618,000.0 | 86,819,000.0 | 71,420,164.0 | 73,672,987.0 | — |
Owes vs Owns
IRADIMED CORPORATION owed $0.12 for every $1 it owned in Jun 2026, down from $0.14 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.12× | 0.13× | 0.12× | 0.23× | 0.14× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
IRADIMED CORPORATION Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 47.0%Receivables 12.6%Inventory 10.7%Fixed assets (tangible) 21.9%Intangible assets 3.1%Other assets 4.7%
How it's funded — Dec 2025
Payables 1.7%Other liabilities 11.3%Shareholders' equity 87.0%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 51.2 | 52.2 | 49.8 | 58.0 |
| Receivables | 13.7 | 10.6 | 12.2 | 13.3 |
| Inventory | 11.6 | 10.4 | 12.8 | 5.4 |
| Fixed assets (tangible) | 23.9 | 16.8 | 11.3 | 4.6 |
| Intangible assets | 3.4 | 3.1 | 2.5 | 2.1 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 5.1 | 5.2 | 3.5 | 2.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.2 | 0.4 | 0.3 |
| Long-term debt | 0.0 | 0.0 | 1.6 | 1.9 |
| Payables | 1.8 | 1.9 | 1.9 | 1.8 |
| Other liabilities | 12.3 | 9.5 | 16.8 | 7.8 |
| Shareholders' equity | 94.6 | 86.8 | 71.4 | 73.7 |
| Net tangible assets | 91.2 | 83.7 | 68.9 | 71.6 |
IRADIMED CORPORATION Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 24,947,000.0 | 25,624,000.0 | 13,465,012.0 | 10,042,711.0 | — |
| Investing Activities | -8,421,000.0 | -8,817,000.0 | -8,007,167.0 | -1,374,997.0 | — |
| Financing Activities | -17,601,000.0 | -14,336,000.0 | -13,656,511.0 | -12,706,400.0 | — |